BiondVax Pharmaceuticals Ltd.
BVXV · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $2,748 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $5,765 | $10,341 | $16,004 | $68,645 |
| G&A Expenses | $0 | $23,979 | $16,136 | $9,354 |
| SG&A Expenses | $5,296 | $23,979 | $5,189 | $9,354 |
| Sales & Mktg Exp. | $0 | $0 | -$10,947 | $0 |
| Other Operating Expenses | $0 | $509 | -$23,475 | $352 |
| Operating Expenses | $11,061 | $34,829 | -$2,281 | $78,351 |
| Operating Income | -$11,061 | -$34,829 | $1,040 | -$78,351 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $5,265 | -$5,149 | -$2,425 | -$30,843 |
| Pre-Tax Income | -$5,796 | -$39,978 | -$1,385 | -$109,194 |
| Tax Expense | -$5,265 | $10,832 | -$8,201 | $14,918 |
| Net Income | -$531 | -$50,810 | $6,815 | -$124,112 |
| % Margin | – | – | – | – |
| EPS | -0.2 | -36 | 6.15 | -151.98 |
| % Growth | 99.4% | -685.4% | 104% | – |
| EPS Diluted | -0.2 | -36 | 6.15 | -151.98 |
| Weighted Avg Shares Out | 2,591 | 1,411 | 1,108 | 817 |
| Weighted Avg Shares Out Dil | 2,591 | 1,411 | 1,108 | 817 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5,265 | $3 | $1,195 | $4 |
| Interest Expense | $0 | $10,832 | $4,861 | $14,918 |
| Depreciation & Amortization | $562 | $2,385 | $2,436 | $1,493 |
| EBITDA | -$10,499 | -$26,761 | $5,912 | -$92,783 |
| % Margin | – | – | – | – |